Morphosys Ag ADR (NQ: MOR )
3.940 UNCHANGED Streaming Delayed Price Updated: 3:59 PM EDT, Mar 24, 2023 Add to My Watchlist
Press Releases about Morphosys Ag ADR
MorphoSys AG: Financial Calendar 2023
November 28, 2022
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary U.S. net product sales of Monjuvi® (tafasitamab-cxix) for the second quarter 2022...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and...
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
March 22, 2022
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following